Evidence map›Paper›PMID 31533053›Full record

ArticleImmunity2019

Scoring a HAT-Trick against Lymphoma.

Oliver Bannard

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Oliver BannardMRC Human Immunology Unit, Nuffield Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS, UK. Electronic address: oliver.bannard@ndm.ox.ac.uk.
MRC Human Immunology Unit · GB

Funding

Wellcome Trust 105654/Z/14/Z
6 · The paper itself

Abstract

The genes encoding the histone acetyltransferases (HATs) CREBB-binding protein (CREBBP) and EP300 are commonly mutated in germinal-center-derived B cell lymphomas, and their inactivation is thought to contribute to lymphomagenesis. In this issue of Immunity, Meyer et al. (2019) demonstrate that the somatic inactivation of one histone modifying enzyme might leave lymphomas uniquely sensitive to antagonists of the other.

Indexed as

Carrier ProteinsLymphoma, Large B-Cell, DiffuseB-LymphocytesCREB-Binding ProteinE1A-Associated p300 ProteinEpigenesis, GeneticGerminal CenterHumansCarrier ProteinsCREB-Binding ProteinCREBBP protein, humanE1A-Associated p300 ProteinEP300 protein, human

Identifiers

PMID31533053
OpenAlexW2973707820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.